Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults.

Secondary end points included changes from baseline in urine volume output compared with placebo, collected for 48 h before and after each treatment period.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

Safety was the primary end point.

What Was Measured

Topics PubMed links to this paper include Glucagon-Like Peptide 2, Intestinal Absorption, Intestinal Failure, Peptides and Short Bowel Syndrome.

The authors tagged it with the keywords glucagon-like peptide-2, intestinal adaptation and parenteral support.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (JPEN. Journal of parenteral and enteral nutrition), a journal based in United States.

More context: the Glucagon compound page, all human trials.